Interferon alpha hybrid

Drug Profile

Interferon alpha hybrid

Latest Information Update: 12 Aug 2016

Price : $50

At a glance

  • Originator University of Strathclyde
  • Developer Alfacyte
  • Class Antineoplastics; Antivirals; Interferons
  • Mechanism of Action Cytokine modulators; Interleukin-17 inhibitors; Leukocyte inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Autoimmune disorders; Food hypersensitivity

Highest Development Phases

  • Research Autoimmune disorders; Food hypersensitivity

Most Recent Events

No Data Available
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top